# Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

> **NCT00038220** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 40 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lopinavir/ritonavir
- **DRUG:** Efavirenz
- **DRUG:** Lamivudine
- **DRUG:** Tenofovir DF

## Key facts

- **NCT ID:** NCT00038220
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (—)
- **Last updated:** 2006-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038220, "Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00038220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*